Compare ATR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATR | PCVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.0B |
| IPO Year | 1995 | 2020 |
| Metric | ATR | PCVX |
|---|---|---|
| Price | $127.17 | $61.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $162.25 | $117.30 |
| AVG Volume (30 Days) | 430.8K | ★ 3.6M |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 6.51 | N/A |
| EPS | ★ 2.48 | N/A |
| Revenue | ★ $3,777,181,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $51.31 | ★ N/A |
| Revenue Growth | ★ 5.42 | N/A |
| 52 Week Low | $103.23 | $39.87 |
| 52 Week High | $146.24 | $90.75 |
| Indicator | ATR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 47.75 |
| Support Level | $119.45 | $52.91 |
| Resistance Level | $127.24 | $63.08 |
| Average True Range (ATR) | 2.07 | 3.56 |
| MACD | 0.73 | -0.81 |
| Stochastic Oscillator | 78.84 | 16.90 |
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.